In vitro and in vivo sensitization of SW620 metastatic colon cancer cells to CDDP-induced apoptosis by the nitric oxide donor DETANONOate: Involvement of AIF

Nitric Oxide - Biology and Chemistry

Volumn 20, Issue 3, 2009, Pages 182-194

  Huerta, Sergio ^a   Baay Guzman, Guillermina ^b,c   Gonzalez Bonilla, Cesar R ^b   Livingston, Edward H ^a   Huerta Yepez, Sara ^b,c   Bonavida, Benjamin ^d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

^c INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apoptosis; Chemoresistance; Colon cancer; DETANONOate; Nitric oxide donors

Indexed keywords

APOPTOSIS INDUCING FACTOR; CISPLATIN; DETANONOATE; NITRIC OXIDE DONOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CLINICAL ARTICLE; COLON ADENOCARCINOMA; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; APOPTOSIS INDUCING FACTOR; CELL LINE, TUMOR; COLONIC NEOPLASMS; DRUG THERAPY, COMBINATION; HUMANS; LACTATES; MICE; NEOPLASM METASTASIS; NITRIC OXIDE DONORS; NITROSO COMPOUNDS; PHENOLS; RNA, SMALL INTERFERING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 61849182029     PISSN: 10898603     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.niox.2008.11.006     Document Type: Article

References (85)

1. Jamieson E.R., and Lippard S.J. Structure, recognition, and processing of cisplatin-DNA adducts. Chem. Rev. 99 (1999) 2467-2498
2. Wang D., and Lippard S.J. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov. 4 (2005) 307-320
3. Chaney S.G., Campbell S.L., Bassett E., and Wu Y. Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. Crit Rev. Oncol. Hematol. 53 (2005) 3-11
4. Hewitt R.E., McMarlin A., Kleiner D., Wersto R., Martin P., Tsokos M., Stamp G.W., and Stetler-Stevenson W.G. Validation of a model of colon cancer progression. J. Pathol. 192 (2000) 446-454
5. Huerta S., Harris D.M., Jazirehi A., Bonavida B., Elashoff D., Livingston E.H., and Heber D. Gene expression profile of metastatic colon cancer cells resistant to cisplatin-induced apoptosis. Int. J. Oncol. 22 (2003) 663-670
6. Huerta S., Heinzerling J.H., Nguiano-Hernandez Y.M., Huerta-Yepez S., Lin J., Chen D., Bonavida B., and Livingston E.H. Modification of gene products involved in resistance to apoptosis in metastatic colon cancer cells: roles of Fas, Apaf-1, NFkappaB, IAPs, Smac/DIABLO, and AIF. J. Surg. Res. 142 (2007) 184-194
7. Bilir A., Erguven M., Oktem G., Ozdemir A., Uslu A., Aktas E., and Bonavida B. Potentiation of cytotoxicity by combination of imatinib and chlorimipramine in glioma. Int. J. Oncol. 32 (2008) 829-839
8. Bonavida B., Huerta-Yepez S., Goodglick L., Mizutani Y., and Miki T. Can we develop biomarkers that predict response of cancer patients to immunotherapy?. Biomarkers 10 Suppl. 1 (2005) S69-S76
9. Garban H.J., and Bonavida B. Nitric oxide sensitizes ovarian tumor cells to Fas-induced apoptosis. Gynecol. Oncol. 73 (1999) 257-264
10. Huerta-Yepez S., Vega M., Jazirehi A., Garban H., Hongo F., Cheng G., and Bonavida B. Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-xl expression. Oncogene 23 (2004) 4993-5003
11. Bratasz A., Weir N.M., Parinandi N.L., Zweier J.L., Sridhar R., Ignarro L.J., and Kuppusamy P. Reversal to cisplatin sensitivity in recurrent human ovarian cancer cells by NCX-4016, a nitro derivative of aspirin. Proc. Natl. Acad. Sci. USA 103 (2006) 3914-3919
12. Bonavida B., Khineche S., Huerta-Yepez S., and Garban H. Therapeutic potential of nitric oxide in cancer. Drug Resist. Updat. 9 (2006) 157-173
13. Huerta S., Chilka S., and Bonavida B. Nitric oxide donors: novel cancer theraperutics. Int. J. Oncol. 33 (2008) 909-928
14. Huerta S., Srivatsan E.S., Venkatesan N., Peters J., Moatamed F., Renner S., and Livingston E.H. Alternative mRNA splicing in colon cancer causes loss of expression of neural cell adhesion molecule. Surgery 130 (2001) 834-843
15. Huerta S., Srivatsan E.S., Venkatasan N., and Livingston E.H. Human colon cancer cells deficient in DCC produce abnormal transcripts in progression of carcinogenesis. Dig. Dis. Sci. 46 (2001) 1884-1891
16. S. Huerta, R.H. Amirkhan, A.A. Siddiqui, E.H. Livingston, S. Huerta-Yepez, Apoptosis inducing factor is decreased in metastatic colon cancer in ex-vivo models of colon carcinogenesis by tissue microarray, J. Clin. Onc. (ASCO Annual Meeting Proceedings) 25 (2007) 14531.
17. Huerta S., Irwin R.W., Heber D., Go V.L., Koeffler H.P., Uskokovic M.R., and Harris D.M. 1alpha,25-(OH)(2)-D(3) and its synthetic analogue decrease tumor load in the Apc(min) mouse. Cancer Res. 62 (2002) 741-746
18. Huerta-Yepez S., Vega M., Garban H., and Bonavida B. Involvement of the TNF-alpha autocrine-paracrine loop, via NF-kappaB and YY1, in the regulation of tumor cell resistance to Fas-induced apoptosis. Clin. Immunol. 120 (2006) 297-309
19. Huerta S., Anguiano-Hernandez Y., Gonzalez-Bonilla C.R., Huerta-Yepez S., and Livingston E.H. DETA/NONOate-mediated chemosensitixation to cisplatin-induced apoptotis of colon cancer in vitro and in vivo. J. Surg. Res. 137 (2007) 271
20. Hanigan M.H., Gallagher B.C., Townsend D.M., and Gabarra V. Gamma-glutamyl transpeptidase accelerates tumor growth and increases the resistance of tumors to cisplatin in vivo. Carcinogenesis 20 (1999) 553-559
21. Zhang R., Zhang L., Zhang Z., Wang Y., Lu M., Lapointe M., and Chopp M. A nitric oxide donor induces neurogenesis and reduces functional deficits after stroke in rats. Ann. Neurol. 50 (2001) 602-611
22. Huerta S., Goulet E.J., and Livingston E.H. Colon cancer and apoptosis. Am. J. Surg. 191 (2006) 517-526
23. Foster J.H. Treatment of metastatic disease of the liver: a skeptic's view. Semin. Liver Dis. 4 (1984) 170-179
24. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., and Thun M.J. Cancer statistics. CA Cancer J. Clin. 58 2008 (2008) 71-96
25. Wolpin B.M., Meyerhardt J.A., Mamon H.J., and Mayer R.J. Adjuvant treatment of colorectal cancer. CA Cancer J. Clin. 57 (2007) 168-185
26. Huerta S. Recent advances in the molecular diagnosis and prognosis of colorectal cancer. Expert Rev. Mol. Diagn. 8 (2008) 277-288
27. O'Connell J.B., Maggard M.A., and Ko C.Y. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J. Natl. Cancer Inst. 96 (2004) 1420-1425
28. Lievre A., Bachet J.B., Boige V., Cayre A., Le C.D., Buc E., Ychou M., Bouche O., Landi B., Louvet C., Andre T., Bibeau F., Diebold M.D., Rougier P., Ducreux M., Tomasic G., Emile J.F., Penault-Llorca F., and Laurent-Puig P. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol. 26 (2008) 374-379
29. Millan A., and Huerta S. Apoptosis-Inducing Factor and Colon Cancer. J. Surg. Res. 151 (2009) 163-170
30. Wang S., Yan-Neale Y., Cai R., Alimov I., and Cohen D. Activation of mitochondrial pathway is crucial for tumor selective induction of apoptosis by LAQ824. Cell Cycle 5 (2006) 1662-1668
31. Ostrakhovitch E.A., and Cherian M.G. Inhibition of extracellular signal regulated kinase (ERK) leads to apoptosis inducing factor (AIF) mediated apoptosis in epithelial breast cancer cells: the lack of effect of ERK in p53 mediated copper induced apoptosis. J. Cell. Biochem. 95 (2005) 1120-1134
32. Pratt M.A., Niu M.Y., and Renart L.I. Regulation of survivin by retinoic acid and its role in paclitaxel-mediated cytotoxicity in MCF-7 breast cancer cells. Apoptosis 11 (2006) 589-605
33. Shrivastava A., Tiwari M., Sinha R.A., Kumar A., Balapure A.K., Bajpai V.K., Sharma R., Mitra K., Tandon A., and Godbole M.M. Molecular iodine induces caspase-independent apoptosis in human breast carcinoma cells involving the mitochondria-mediated pathway. J. Biol. Chem. 281 (2006) 19762-19771
34. Soto-Cerrato V., Montaner B., Martinell M., Vilaseca M., Giralt E., and Perez-Tomas R. Cell cycle arrest and proapoptotic effects of the anticancer cyclodepsipeptide serratamolide (AT514) are independent of p53 status in breast cancer cells. Biochem. Pharmacol. 71 (2005) 32-41
35. Ambrose M., Ryan A., O'Sullivan G.C., Dunne C., and Barry O.P. Induction of apoptosis in renal cell carcinoma by reactive oxygen species: involvement of extracellular signal-regulated kinase 1/2, p38delta/gamma, cyclooxygenase-2 down-regulation, and translocation of apoptosis-inducing factor. Mol. Pharmacol. 69 (2006) 1879-1890
36. Panka D.J., Wang W., Atkins M.B., and Mier J.W. The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res. 66 (2006) 1611-1619
37. Yang J., Amiri K.I., Burke J.R., Schmid J.A., and Richmond A. BMS-345541 targets inhibitor of kappaB kinase, induces apoptosis in melanoma: involvement of nuclear factor kappaB and mitochondria pathways. Clin. Cancer Res. 12 (2006) 950-960
38. Garcia-Morales P., Gomez-Martinez A., Carrato A., Martinez-Lacaci I., Barbera V.M., Soto J.L., Carrasco-Garcia E., Menendez-Gutierrez M.P., Castro-Galache M.D., Ferragut J.A., and Saceda M. Histone deacetylase inhibitors induced caspase-independent apoptosis in human pancreatic adenocarcinoma cell lines. Mol. Cancer Ther. 4 (2005) 1222-1230
39. Cho W.H., Choi C.H., Park J.Y., Kang S.K., and Kim Y.K. 15-deoxy-(Delta12,14)-prostaglandin J2 (15d-PGJ2) induces cell death through caspase-independent mechanism in A172 human glioma cells. Neurochem. Res. 31 (2006) 1247-1254
40. Fu Y.M., Zhang H., Ding M., Li Y.Q., Fu X., Yu Z.X., and Meadows G.G.. Selective amino acid restriction targets mitochondria to induce apoptosis of androgen-independent prostate cancer cells. J. Cell. Physiol 209 (2006) 522-534
41. O'Connor K., Gill C., Tacke M., Rehmann F.J., Strohfeldt K., Sweeney N., Fitzpatrick J.M., and Watson R.W. Novel titanocene anti-cancer drugs and their effect on apoptosis and the apoptotic pathway in prostate cancer cells. Apoptosis 11 (2006) 1205-1214
42. Andjilani M., Droz J.P., Benahmed M., and Tabone E. Alpha6 integrin subunit mediates laminin enhancement of cisplatin-induced apoptosis in testicular tumor germ cells. Int. J. Cancer 117 (2005) 68-81
43. Gomez-Benito M., Marzo I., Anel A., and Naval J. Farnesyltransferase inhibitor BMS-214662 induces apoptosis in myeloma cells through PUMA up-regulation, Bax and Bak activation, and Mcl-1 elimination. Mol. Pharmacol. 67 (2005) 1991-1998
44. Carlo-Stella C., Di N.M., Turco M.C., Cleris L., Lavazza C., Longoni P., Milanesi M., Magni M., Ammirante M., Leone A., Nagy Z., Gioffre W.R., Formelli F., and Gianni A.M. The anti-human leukocyte antigen-DR monoclonal antibody 1D09C3 activates the mitochondrial cell death pathway and exerts a potent antitumor activity in lymphoma-bearing nonobese diabetic/severe combined immunodeficient mice. Cancer Res. 66 (2006) 1799-1808
45. Kuhar M., Sen S., and Singh N. Role of mitochondria in quercetin-enhanced chemotherapeutic response in human non-small cell lung carcinoma H-520 cells. Anticancer Res. 26 (2006) 1297-1303
46. Leung H.W., Wu C.H., Lin C.H., and Lee H.Z. Luteolin induced DNA damage leading to human lung squamous carcinoma CH27 cell apoptosis. Eur. J. Pharmacol. 508 (2005) 77-83
47. Fu Y.R., Qiu Z.Y., and Yan Y.R. Effect of hydroxycamptothecin on apoptosis-inducing factor (AIF) expression and on AIF translocation in human hepatocellular cancer cell SMMC-7721. Zhonghua Gan Zang. Bing. Za Zhi. 14 (2006) 285-288
48. Skvortsova I., Skvortsov S., Popper B.A., Haidenberger A., Saurer M., Gunkel A.R., Zwierzina H., and Lukas P. Rituximab enhances radiation-triggered apoptosis in non-Hodgkin's lymphoma cells via caspase-dependent and -independent mechanisms. J. Radiat. Res. (Tokyo) 47 (2006) 183-196
49. Daugas E., Nochy D., Ravagnan L., Loeffler M., Susin S.A., Zamzami N., and Kroemer G. Apoptosis-inducing factor (AIF): a ubiquitous mitochondrial oxidoreductase involved in apoptosis. FEBS Lett. 476 (2000) 118-123
50. Park Y.C., Jeong J.H., Park K.J., Choi H.J., Park Y.M., Jeong B.K., Higuchi Y., and Yoo Y.H. Sulindac activates nuclear translocation of AIF, DFF40 and endonuclease G but not induces oligonucleosomal DNA fragmentation in HT-29 cells. Life Sci. 77 (2005) 2059-2070
51. Onoda T., Ono T., Dhar D.K., Yamanoi A., and Nagasue N. Tetracycline analogues (doxycycline and COL-3) induce caspase-dependent and -independent apoptosis in human colon cancer cells. Int. J. Cancer 118 (2006) 1309-1315
52. Rashmi R., Kumar S., and Karunagaran D. Human colon cancer cells lacking Bax resist curcumin-induced apoptosis and Bax requirement is dispensable with ectopic expression of Smac or downregulation of Bcl-XL. Carcinogenesis 26 (2005) 713-723
53. Diaz G.D., Li Q., and Dashwood R.H. Caspase-8 and apoptosis-inducing factor mediate a cytochrome c-independent pathway of apoptosis in human colon cancer cells induced by the dietary phytochemical chlorophyllin. Cancer Res. 63 (2003) 1254-1261
54. Erhart L.M., Lankat-Buttgereit B., Schmidt H., Wenzel U., Daniel H., and Goke R. Flavone initiates a hierarchical activation of the caspase-cascade in colon cancer cells. Apoptosis 10 (2005) 611-617
55. Ho Y.S., Wu C.H., Chou H.M., Wang Y.J., Tseng H., Chen C.H., Chen L.C., Lee C.H., and Lin S.Y. Molecular mechanisms of econazole-induced toxicity on human colon cancer cells: G0/G1 cell cycle arrest and caspase 8-independent apoptotic signaling pathways. Food Chem. Toxicol. 43 (2005) 1483-1495
56. Lin J.C., Ho Y.S., Lee J.J., Liu C.L., Yang T.L., and Wu C.H. Induction of apoptosis and cell-cycle arrest in human colon cancer cells by meclizine. Food Chem. Toxicol. 45 (2007) 935-944
57. Schmitt E., Maingret L., Puig P.E., Rerole A.L., Ghiringhelli F., Hammann A., Solary E., Kroemer G., and Garrido C. Heat shock protein 70 neutralization exerts potent antitumor effects in animal models of colon cancer and melanoma. Cancer Res. 66 (2006) 4191-4197
58. Huerta S., Anguiano-Hernandez Y.M., Goulet E.J., Huerta-Yepez S., and Livingston E.H. Decreased levels of AIF renders resistance to oxaliplatin mediated apoptosis in the progression of colon cancer carcinogenesis beyond caspase-3 activity. American Journal of Gastroenterology 101 (2006) S196
59. Modjtahedi N., Giordanetto F., Madeo F., Madeo F., and Kroemer G. Apoptosis-inducing factor: vital and lethal. Trends Cell Biol. 16 (2006) 264-272
60. Susin S.A., Lorenzo H.K., Zamzami N., Marzo I., Snow B.E., Brothers G.M., Mangion J., Jacotot E., Costantini P., Loeffler M., Larochette N., Goodlett D.R., Aebersold R., Siderovski D.P., Penninger J.M., and Kroemer G. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 397 (1999) 441-446
61. Huerta S., Goulet E.J., Huerta-Yepez S., and Livingston E.H. Screening and detection of apoptosis. J. Surg. Res. 139 (2007) 143-156
62. Yu S.W., Andrabi S.A., Wang H., Kim N.S., Poirier G.G., Dawson T.M., and Dawson V.L. Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death. Proc. Natl. Acad. Sci. USA 103 (2006) 18314-18319
63. Wang Y., Jatkoe T., Zhang Y., Mutch M.G., Talantov D., Jiang J., McLeod H.L., and Atkins D. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J. Clin. Oncol. 22 (2004) 1564-1571
64. Urbano A., Lakshmanan U., Choo P.H., Kwan J.C., Ng P.Y., Guo K., Dhakshinamoorthy S., and Porter A. AIF suppresses chemical stress-induced apoptosis and maintains the transformed state of tumor cells. EMBO J. 24 (2005) 2815-2826
65. Forrester K., Ambs S., Lupold S.E., Kapust R.B., Spillare E.A., Weinberg W.C., Felley-Bosco E., Wang X.W., Geller D.A., Tzeng E., Billiar T.R., and Harris C.C. Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase expression by wild-type p53. Proc. Natl. Acad. Sci. USA 93 (1996) 2442-2447
66. Messmer U.K., Ankarcrona M., Nicotera P., and Brune B. p53 expression in nitric oxide-induced apoptosis. FEBS Lett. 355 (1994) 23-26
67. Messmer U.K., and Brune B. Nitric oxide-induced apoptosis: p53-dependent and p53-independent signalling pathways. Biochem. J. 319 Pt 1 (1996) 299-305
68. Glockzin S., von K.A., Scheffner M., and Brune B. Activation of the cell death program by nitric oxide involves inhibition of the proteasome. J. Biol. Chem. 274 (1999) 19581-19586
69. Li C.Q., Robles A.I., Hanigan C.L., Hofseth L.J., Trudel L.J., Harris C.C., and Wogan G.N. Apoptotic signaling pathways induced by nitric oxide in human lymphoblastoid cells expressing wild-type or mutant p53. Cancer Res. 64 (2004) 3022-3029
70. Boyd C.S., and Cadenas E. Nitric oxide and cell signaling pathways in mitochondrial-dependent apoptosis. Biol. Chem. 383 (2002) 411-423
71. Kroncke K.D., Fehsel K., and Kolb-Bachofen V. Inducible nitric oxide synthase in human diseases. Clin. Exp. Immunol. 113 (1998) 147-156
72. Lala P.K., and Chakraborty C. Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol. 2 (2001) 149-156
73. Shimaoka M., Iida T., Ohara A., Taenaka N., Mashimo T., Honda T., and Yoshiya I. NOC, a nitric-oxide-releasing compound, induces dose dependent apoptosis in macrophages. Biochem. Biophys. Res. Commun. 209 (1995) 519-526
74. Heller R., Polack T., Grabner R., and Till U. Nitric oxide inhibits proliferation of human endothelial cells via a mechanism independent of cGMP. Atherosclerosis 144 (1999) 49-57
75. Lau Y.T., and Ma W.C.. Nitric oxide inhibits migration of cultured endothelial cells. Biochem. Biophys. Res. Commun. 221 (1996) 670-674
76. Pipili-Synetos E., Papageorgiou A., Sakkoula E., Sotiropoulou G., Fotsis T., Karakiulakis G., and Maragoudakis M.E. Inhibition of angiogenesis, tumour growth and metastasis by the NO-releasing vasodilators, isosorbide mononitrate and dinitrate. Br. J. Pharmacol. 116 (1995) 1829-1834
77. Mortensen K., Christensen I.J., Nielsen H.J., Hansen U., and Larsson L.I. High expression of endothelial cell nitric oxide synthase in peritumoral microvessels predicts increased disease-free survival in colorectal cancer. Cancer Lett. 216 (2004) 109-114
78. Son K.K., and Hall K.J. Nitric oxide-mediated tumor cell killing of cisplatin-based interferon-gamma gene therapy in murine ovarian carcinoma. Cancer Gene Ther. 7 (2000) 1324-1328
79. Hardman W.E., Moyer M.P., and Cameron I.L. Efficacy of treatment of colon, lung and breast human carcinoma xenografts with: doxorubicin, cisplatin, irinotecan or topotecan. Anticancer Res. 19 (1999) 2269-2274
80. Cappuzzo F., Finocchiaro G., Rossi E., Janne P.A., Carnaghi C., Calandri C., Bencardino K., Ligorio C., Ciardiello F., Pressiani T., Destro A., Roncalli M., Crino L., Franklin W.A., Santoro A., and Varella-Garcia M. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann. Oncol. 19 (2008) 717-723
81. Sartore-Bianchi A., Moroni M., Veronese S., Carnaghi C., Bajetta E., Luppi G., Sobrero A., Barone C., Cascinu S., Colucci G., Cortesi E., Nichelatti M., Gambacorta M., and Siena S. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J. Clin. Oncol. 25 (2007) 3238-3245
82. Khambata-Ford S., Garrett C.R., Meropol N.J., Basik M., Harbison C.T., Wu S., Wong T.W., Huang X., Takimoto C.H., Godwin A.K., Tan B.R., Krishnamurthi S.S., Burris III H.A., Poplin E.A., Hidalgo M., Baselga J., Clark E.A., and Mauro D.J.. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J. Clin. Oncol. 25 (2007) 3230-3237
83. Taylor A.L., Ziesche S., Yancy C., Carson P., D'Agostino Jr. R., Ferdinand K., Taylor M., Adams K., Sabolinski M., Worcel M., and Cohn J.N. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N. Engl. J. Med. 351 (2004) 2049-2057
84. Yasuda H., Yamaya M., Nakayama K., Sasaki T., Ebihara S., Kanda A., Asada M., Inoue D., Suzuki T., Okazaki T., Takahashi H., Yoshida M., Kaneta T., Ishizawa K., Yamanda S., Tomita N., Yamasaki M., Kikuchi A., Kubo H., and Sasaki H. Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer. J. Clin. Oncol. 24 (2006) 688-694
85. Yasuda H., Nakayama K., Watanabe M., Suzuki S., Fuji H., Okinaga S., Kanda A., Zayasu K., Sasaki T., Asada M., Suzuki T., Yoshida M., Yamanda S., Inoue D., Kaneta T., Kondo T., Takai Y., Sasaki H., Yanagihara K., and Yamaya M. Nitroglycerin treatment may enhance chemosensitivity to docetaxel and carboplatin in patients with lung adenocarcinoma. Clin. Cancer Res 12 (2006) 6748-6757